stockrow
Friday 6 November 2026
Export YI’s income statement to Excel — free account
111, Inc. Sponsored ADR
YI Healthcare Medical Distribution
111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024.
- Revenue
- −29.6%
- EPS
- −113.7%
- Free cash flow
- −185.7%
- Total debt
- +82.5%
Quarter to March 2026, against a year earlier
2.95
0.05
−1.67%
Follow YI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Mar ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 132 | 145 | 260 | 568 | 1,257 | 1,950 | 1,960 | 2,105 | 1,973 | 1,795 | 1,651 | +33.6% | 2,398 | 2,754 | — | +23.9% | |
| Gross margin, % | 9.09 | 9.46 | 5.84 | 4.18 | 4.46 | 5.00 | 6.21 | 5.68 | 5.76 | 5.76 | 5.74 | (3.3) pt | ||||||
| EBT | (55) | (38) | (56) | (72) | (72) | (97) | (55) | (50) | (3) | (3) | (6) | (27.1%) | ||||||
| EBT margin, % | (41.67) | (25.99) | (21.39) | (12.70) | (5.69) | (5.00) | (2.78) | (2.36) | (0.14) | (0.18) | (0.37) | +41.5 pt | ||||||
| Net income | (55) | (38) | (56) | (72) | (72) | (97) | (55) | (50) | (3) | (3) | (3) | (27.0%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 36.67 | 40.28 | 52.24 | 69.37 | 152.58 | 235.11 | 235.21 | 249.74 | 229.63 | 206.35 | 187.78 | +21.2% | |||||
| Earnings | (17.50) | (10.47) | (11.10) | (8.80) | (8.40) | (12.60) | (7.20) | (6.60) | (1.03) | (1.00) | (1.40) | (27.2%) | ||||||
| Cash flow | (16.25) | (8.58) | (10.03) | (8.99) | (2.17) | (13.03) | (0.40) | (7.47) | 4.19 | 1.96 | (1.34) | n/m | ||||||
| Capex | 0.00 | (0.29) | (0.43) | (0.43) | (0.48) | (1.18) | (0.53) | (0.14) | (0.23) | (0.07) | 0.00 | n/m | ||||||
| Free cash flow | (16.25) | (8.86) | (10.46) | (9.42) | (2.65) | (14.21) | (0.93) | (7.61) | 3.96 | 1.89 | (1.34) | n/m | ||||||
| Book value | 43.84 | (39.66) | 35.79 | 13.58 | 7.56 | (2.88) | (7.11) | (9.94) | (10.49) | (11.86) | (12.51) | n/m | ||||||
| Shares, m | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | +10.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.97 | 0.46 | 0.15 | 0.13 | 0.07 | 0.03 | 0.01 | 0.02 | 0.2 | ||||||
| P/B | 0.00 | 0.00 | 1.42 | 4.95 | 9.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.6 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.82 | 0.29 | 0.09 | 0.07 | 0.04 | 0.00 | (0.02) | 0.00 | 0.1 | ||||||
| EV/FCF | 0.00 | 0.00 | 0.00 | (6.31) | (13.54) | (1.45) | (5.85) | (1.11) | 0.27 | (4.71) | (0.28) | (3.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (58) | (31) | (50) | (74) | (18) | (108) | (3) | (63) | 36 | 17 | (12) | n/m | |||||
| Capex | (1) | (1) | (2) | (4) | (4) | (10) | (4) | (1) | (2) | (1) | (8) | (5.5%) | ||||||
| Free cash flow | (58) | (32) | (52) | (77) | (22) | (118) | (8) | (64) | 34 | 16 | (12) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 105 | 80 | 173 | 102 | 190 | 105 | 74 | 27 | 42 | 24 | 21 | (14.9%) | |||||
| Net debt | (92) | (70) | (161) | (87) | (213) | (107) | (108) | (47) | (49) | (61) | (20) | (4.6%) | ||||||
| Shareholders’ equity | 158 | (143) | 178 | 111 | 62 | (24) | (59) | (84) | (90) | (103) | (110) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (36.72) | (25.19) | (32.49) | (31.46) | (20.13) | (21.96) | (12.12) | (11.78) | (2.17) | (2.73) | (3.89) | +34.0 pt | |||||
| ROIC | 0.00 | 0.00 | (213.47) | (180.08) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 51.65 | 31.08 | (313.93) | (49.64) | (80.68) | (547.31) | 145.42 | 77.35 | 10.20 | 9.82 | 12.26 | (41.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 1,117 | 1,350 | 1,932 | 2,189 | 2,114 | 1,657 | 1,520 | 1,238 | 1,063 | — | (0.6%) | |||||
| Revenue/emp, $m | 0.00 | 0.13 | 0.19 | 0.29 | 0.57 | 0.92 | 1.18 | 1.39 | 1.59 | 1.69 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
111, Inc. Sponsored ADR vs peers in Medical Distribution (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HSIC Henry Schein, Inc. | $9.4B | 22.8× | 21.3× | +3.95% (above 0%: growing) | +34.81% (above 0%: growing) | −7.09% (below 0%: shrinking) | 31.84% | 5.56% | Compare |
| AHG Akso Health Group Sponsored ADR | $1.1B | — (loss-making) | — (loss-making) | +263.89% (above 0%: growing) | n/m | −12,975.04% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FOCL FocalTherics | $159.3M | — (loss-making) | — (loss-making) | +38.85% (above 0%: growing) | n/m | +21.49% (above 0%: growing) | 55.59% | (60.83%) | Compare |
| COSM Cosmos Health Inc. | $29.2M | — (loss-making) | — (loss-making) | +28.76% (above 0%: growing) | n/m | +9.39% (above 0%: growing) | 7.96% | (15.41%) | Compare |
| ACH Accendra Health, Inc. | $23.0M | — (loss-making) | — (loss-making) | −10.07% (below 0%: shrinking) | n/m | −1,624.82% (below 0%: shrinking) | 42.95% | (5.73%) | Compare |
| YI 111, Inc. Sponsored ADR | $15.5M | — (loss-making) | — (loss-making) | −29.61% (below 0%: shrinking) | n/m | −185.70% (below 0%: shrinking) | 5.33% | (0.85%) | |
| MEDS DataMeds AI, Inc | $5.5M | — (loss-making) | — | −77.15% (below 0%: shrinking) | n/m | −41.85% (below 0%: shrinking) | 10.24% | (412.67%) | Compare |
| HKPD Cellyan Biotechnology Co., Ltd | $3.4M | — | — | — | — | −90.45% (below 0%: shrinking) | — | — | Compare |
| SNYRQ Synergy CHC Corp. | $1.3M | — (loss-making) | 1.6× | −32.77% (below 0%: shrinking) | n/m | −148.51% (below 0%: shrinking) | 72.29% | (10.32%) | Compare |
| Median of peers | $26.1M | — | — | +3.95% | — | −66.15% | 31.84% | (10.32%) |